Monthly
US$200
Billed every month
Sign in to subscribeApplication numbers, product numbers and original fields are retained. Marketing status is shown as listed in the source.
Currently marketed products: 4 · Counts FDA prescription and OTC marketing categories as listed; discontinued or unknown categories are excluded.
| Application / product number | Brand name (original) | Applicant (original) | Dosage form (original) | Route (original) | Strength (original) | Earliest approval | RLD / RS | Marketing status (original) | Official source |
|---|---|---|---|---|---|---|---|---|---|
| A209040-001 | TAFLUPROST | SANDOZ INC | SOLUTION/DROPS | OPHTHALMIC | TAFLUPROST: 0.0015% | 2022/01/28 | N / N | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| A209051-001 | TAFLUPROST | MICRO LABS LTD | SOLUTION/DROPS | OPHTHALMIC | TAFLUPROST: 0.0015% | 2019/08/19 | N / N | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| A218002-001 | TAFLUPROST | INGENUS PHARMACEUTICALS LLC | SOLUTION/DROPS | OPHTHALMIC | TAFLUPROST: 0.0015% | 2024/04/05 | N / N | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| N202514-001 | ZIOPTAN | THEA PHARMA INC | SOLUTION/DROPS | OPHTHALMIC | TAFLUPROST: 0.0015% | 2012/02/10 | Y / Y | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
*PED rows, substance/product flags, use codes and delisting-request flags are retained without determining legal effect.
This column includes only source rows explicitly flagged DS. A PED row without that flag is not assigned one by this site.
| Application / product number | Patent number | Listed expiration | Substance / product flags | Use code | Delisting request | Official source |
|---|---|---|---|---|---|---|
| N202514-001 | 10864159 | 2029/05/28 | — / Y | U-778 | — | openFDA ↗ |
| N202514-001 | 9999593 | 2029/05/28 | — / Y | — | — | openFDA ↗ |
Latest exclusivity expiration: —
| Application / product number | Exclusivity code | Listed expiration | Official source |
|---|---|---|---|
| Not listed | |||
The four-zero filter applies only to matched rows: catalog holders, NHSA approval numbers, applications under review, and companies filing generics this year. Unmatched rows have no Chinese counts. Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
| Company (original) | Identifier (original) | Source date | Official source |
|---|---|---|---|
| Santen Pharmaceutical Co.,Ltd. | H201504230.0015%(2.5ml:37.5μg) | 2015/07/27 | Official source ↗ |
| Company (original) | Identifier (original) | Source date | Official source |
|---|---|---|---|
| Shenyang Xing Qi Yan Yao Co., Ltd. romanized | 国药准字H202531640.0015%(0.3ml:4.5μg) | — | Official source ↗ |
| Yangtze River Pharmaceutical Group Co., Ltd | 国药准字H202436900.0015%(0.3ml:4.5μg) | — | Official source ↗ |
| Hangzhou Minsheng Pharmaceutical Co., Ltd | 国药准字H202448550.0015%(2.5ml∶37.5μg) | — | Official source ↗ |
| Zhejiang Jian Feng Pharma Co., Ltd. romanized | 国药准字H202435900.0015%(2.5ml: 37.5μg) | — | Official source ↗ |
| Hainan Si Da Pharmaceutical Co., Ltd. romanized | 国药准字H202560770.0015%(0.3ml:4.5μg) | — | Official source ↗ |
| Santen Pharmaceutical Co., Ltd. | 国药准字J201501310.0015%(2.5ml:37.5μg) | — | Official source ↗ |
| Santen Pharmaceutical Co.,Ltd. | 国药准字HJ201910240.0015%(0.3ml:4.5μg) | — | Official source ↗ |
| Chengdu Sheng Di Pharmaceuticals Co., Ltd. romanized | 国药准字H202138550.0015%(0.3ml:4.5μg) | — | Official source ↗ |
| Shaanxi Li Cai Pharma Co., Ltd. romanized | 国药准字H202449140.0015%(0.3ml:4.5μg) | — | Official source ↗ |
| Suzhou Ou Kang Wei Shi Bio Technology Co., Ltd. romanized | 国药准字H202533590.0015%(0.3ml:4.5µg) | — | Official source ↗ |
| Jiangsu An Bi Sheng Pharmaceutical Co., Ltd. romanized | 国药准字H202545640.0015%(0.3ml:4.5μg) | — | Official source ↗ |
| Hubei Min Kang Pharma Group Co., Ltd. romanized | 国药准字H202560670.0015%(0.3ml:4.5μg) | — | Official source ↗ |
| Hainan Si Da Pharmaceutical Co., Ltd. romanized | 国药准字H202560770.0015%(0.3ml:4.5μg) | — | Official source ↗ |
| Santen Pharmaceutical Co.,Ltd. | 国药准字HJ201910240.0015%(0.3ml:4.5μg) | — | Official source ↗ |
| Chengdu Sheng Di Pharmaceuticals Co., Ltd. romanized | 国药准字H202138550.0015%(0.3ml:4.5μg) | — | Official source ↗ |
| Chengdu Sheng Di Pharmaceuticals Co., Ltd. romanized | 国药准字H202138550.0015%(0.3ml:4.5μg) | — | Official source ↗ |
| Santen Pharmaceutical Co.,Ltd. | 国药准字HJ201505280.0015%(2.5ml:37.5μg) | — | Official source ↗ |
| Company (original) | Identifier (original) | Source date | Official source |
|---|---|---|---|
| Shandong Chen Xin Fu Dou Pharma Co., Ltd. romanized | CYHS2503857 | 2025/11/03 | Official source ↗ |
| Hong Yue Technology (Hu Zhou) Co., Ltd. romanized; Hangzhou Minsheng Pharmaceutical Co., Ltd | CYHS2602797 | 2026/11/12 | Official source ↗ |
| Chongqing Ke Rui Pharmaceutical (Group) Co., Ltd. romanized | CYHS2602796 | 2026/11/12 | Official source ↗ |
| Company (original) | Identifier (original) | Source date | Official source |
|---|---|---|---|
| Hong Yue Technology (Hu Zhou) Co., Ltd. romanized; Hangzhou Minsheng Pharmaceutical Co., Ltd | CYHS2602797 | 2026/11/12 | Official source ↗ |
| Chongqing Ke Rui Pharmaceutical (Group) Co., Ltd. romanized | CYHS2602796 | 2026/11/12 | Official source ↗ |
| Company (original) | Identifier (original) | Source date | Official source |
|---|---|---|---|
| Zhejiang Ao Xiang Pharma Co., Ltd. romanized | Y20220000747 | 2026/09/24 | Official source ↗ |
| Jia He Gui Technology Co., Ltd. You Shi Factory romanized | Y20210000395 | 2024/02/08 | Official source ↗ |
| Yang Zi Jiang Pharma Group Jiangsu Hai Ci Bio Pharma Co., Ltd. romanized | Y20210000367 | 2023/06/12 | Official source ↗ |
| Zhejiang Jian Feng Pharma Co., Ltd. romanized | Y20210000093 | 2023/08/16 | Official source ↗ |
| Zhejiang Tian Yu Pharma Co., Ltd. romanized | Y20190000507 | 2026/08/15 | Official source ↗ |
Not loaded
Chinese counts use complete ingredient, dosage-form and route matches. Unmatched and partial rows show name-source matching only and make no finding about Chinese approvals or filings. Trials cover registration-number years 2025/2026 only.
Comparison generated: 2026/11/16 08:41 · openFDA Orange Book ↗
Subscriptions
US$200
Billed every month
Sign in to subscribeUS$540
Billed every three months
US$180 per month
Sign in to subscribeUS$1,920
Billed every year
US$160 per month
Sign in to subscribeSeparate one-time purchase
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
Billed by Creem, our merchant of record · Terms · Refund policy